Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
START-POAF Pilot Trial
NCT05841056Phase 3Recruiting
- Sponsor
- Population Health Research Institute
- Start
- Jun 2024
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amiodarone in Atrial fibrillation (AFib) (2 arms), sponsored by Population Health Research Institute. Primary endpoints: Recruitment rate at 2 years, Cross-over rate at 28 days and 3 more. Started Jun 2024; status: recruiting.
02
Drugs
amiodarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT05841056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05841056.